The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Like many of the best car logos, the Tesla logo was originally conceived to look good on the front of vehicles, which it why ...

With the brand new JDC Burst 1, GLP continues its success story with a significantly more powerful strobe/wash hybrid.

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

New product introductions deliver fun twists on taste and texture—and still others offer dietary health benefits for those ...

In a Monday interview with CNBC’s Jim Cramer, Papa John’s CEO Todd Penegor described how the pizza franchise tweaked its ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

These GLP-1 agonists include semaglutide ... This potentially blinding damage to the light-sensitive tissue lining the back of the eyes often accompanies diabetes when blood sugar levels are ...

Wegovy and Zepbound are part of a GLP-1 class of treatments that has shown unprecedented results for helping people shed weight by decreasing appetite and boosting feelings of fullness.

A large-scale study analyzing data from over 60 million patients finds no evidence that GLP-1 receptor agonists increase suicidality risk in type 2 diabetes patients, challenging previous safety ...